Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

FDA experts to vote on Abbott stent

Drug-coated device could be next to enter market as panel considers report showing strong data vs. competing stent.

Subscribe to Companies
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)
By Aaron Smith, CNNMoney.com staff writer

NEW YORK (CNNMoney.com) -- Food and Drug Administration advisers will decide this week whether they think America is ready for another drug-coated stent.

Experts will vote Thursday on Abbott Labs' (Charts, Fortune 500) experimental Xience stent, and this non-binding vote will be taken into consideration by regulators at a later date.

If Xience gets the green light, it will compete with Boston Scientific's (Charts, Fortune 500) Taxus, which is already on the market, and possibly with Medtronic's (Charts, Fortune 500) Endeavor, which in October was recommended for approval by FDA advisers. In this $3 billion market, it will also compete with the older-model bare metal stents.

Drug-coated stents have been on the U.S. market since 2003. They are wire mesh tubes inserted into arteries during angioplasty to help heart disease patients avoid blood clots. The stents have come under scrutiny for reportedly causing bleeding, though the reports are inconclusive.

Some analysts believe that Abbott has a good shot of getting Xience past the FDA because of recently released reports from Abbott. On Tuesday, Abbott released an update from an earlier study, first released in March, that showed the superiority of Xience over Taxus.

"Based on the clinical data revealed so far - and especially the clear evidence of statistically significant superiority to Boston Scientific's market-leading Taxus - we expect the panel to vote for approval of the Abbott device," said Phil Nalbone, analyst for RBC Capital Markets, in a published report.

Nalbone does not own Abbott stock, though RBC has received compensation from the company in the last 12 months for products and services other than investment banking.  To top of page

Photo Galleries
Best cars for the super-rich The Robb Report has selected these as the best new cars and SUVs for anyone who doesn't have to worry about how much they spend. More
Banned! 10 things you won't find in China China says it wants to open its economy more to the rest of the world, but Beijing keeps a tight grip on technology and access to media. These 10 items are still off limits. More
A morning at the AltSchool, an education startup that Silicon Valley is crazy about The AltSchool is a system of "micro schools" and an education software maker that has raised about $133 million from investors like Andreessen Horowitz and Mark Zuckerberg and Priscilla Chan's philanthropic fund. More
Sponsors